Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MASI 
Masimo Corporation (MASI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MASI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $187.57
1 Year Target Price $187.57
| 4 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 13.63% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.25B USD | Price to earnings Ratio - | 1Y Target Price 187.57 |
Price to earnings Ratio - | 1Y Target Price 187.57 | ||
Volume (30-day avg) 9 | Beta 1.21 | 52 Weeks Range 107.98 - 194.88 | Updated Date 08/15/2025 |
52 Weeks Range 107.98 - 194.88 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 1.22 | Actual 1.33 |
Profitability
Profit Margin -21.32% | Operating Margin (TTM) 17.12% |
Management Effectiveness
Return on Assets (TTM) 1.84% | Return on Equity (TTM) -22.37% |
Valuation
Trailing PE - | Forward PE 40 | Enterprise Value 8965097679 | Price to Sales(TTM) 3.83 |
Enterprise Value 8965097679 | Price to Sales(TTM) 3.83 | ||
Enterprise Value to Revenue 4.16 | Enterprise Value to EBITDA 29.56 | Shares Outstanding 54324800 | Shares Floating 45310696 |
Shares Outstanding 54324800 | Shares Floating 45310696 | ||
Percent Insiders 5.97 | Percent Institutions 103.33 |
Upturn AI SWOT
Masimo Corporation
Company Overview
History and Background
Masimo Corporation was founded in 1989. Initially focused on improving pulse oximetry technology, it has grown into a global medical technology company with innovations in noninvasive monitoring.
Core Business Areas
- Healthcare: Develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, including pulse oximetry, capnography, and other advanced monitoring solutions used in hospitals, emergency medical services, and home healthcare settings.
- Consumer: Develops, manufactures and markets a variety of audio and wearable products for the consumer market.
Leadership and Structure
Joe Kiani is the Chairman and CEO. The company has a typical corporate structure with departments such as R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- Product Name 1: Rainbow SET Pulse CO-Oximetry: A noninvasive blood constituent monitoring platform. Market share is significant in hospitals globally. Competitors include Medtronic, Philips, and GE Healthcare. The market share of this product is approximately 50%.
- Product Name 2: ISA Capnography: A sidestream capnography technology for monitoring carbon dioxide levels. Market share in the respiratory monitoring market is significant. Competitors include Philips, Medtronic, and Smiths Medical. The market share of this product is approximately 20%.
- Product Name 3: W1 Health Watch: A wearable health tracking device. Competitors include Apple, Fitbit, Samsung and Garmin.
Market Dynamics
Industry Overview
The medical device industry is experiencing growth driven by technological advancements, aging populations, and increasing healthcare spending.
Positioning
Masimo is positioned as a leader in noninvasive patient monitoring, known for its innovative technologies and high accuracy. The company is also attempting to disrupt the consumer wearable market.
Total Addressable Market (TAM)
The global patient monitoring market is expected to reach $55.1 billion by 2033. Masimo is well positioned to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Innovative technology
- Extensive patent portfolio
- Established distribution network
Weaknesses
- Reliance on hospital sales
- Dependence on a few key products
- High R&D costs
Opportunities
- Expansion into emerging markets
- Development of new monitoring technologies
- Partnerships with other healthcare providers
- Growth in the consumer market
Threats
- Increasing competition
- Price pressures
- Regulatory changes
- Intellectual property infringement
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Philips (PHG)
- GE HealthCare Technologies (GEHC)
Competitive Landscape
Masimou2019s advantages include its innovative technology and strong brand reputation. Disadvantages include its reliance on hospital sales and increasing competition.
Major Acquisitions
Sound United
- Year: 2022
- Acquisition Price (USD millions): 1025
- Strategic Rationale: Masimo acquired Sound United to expand into the consumer audio and home entertainment market and to leverage their audio technology expertise.
Growth Trajectory and Initiatives
Historical Growth: Masimo has experienced significant growth in revenue over the past decade, driven by its innovative products and expanding market reach.
Future Projections: Analysts project continued growth for Masimo, driven by increased adoption of its technologies and expansion into new markets. Expecting single digit percentage revenue growth.
Recent Initiatives: Recent initiatives include the acquisition of Sound United, product development of the W1 Health Watch and expansion into consumer market.
Summary
Masimo is a leader in noninvasive patient monitoring with a strong market position, although the recent Sound United acquisition has negatively impacted the financial statement. The company's innovative technology and brand reputation are significant strengths. However, increasing competition and the need to successfully integrate Sound United will be critical for future growth. The company will also need to look out for margin pressure which has decreased in the last three years.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data is based on publicly available information and may not be entirely accurate or complete.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Masimo Corporation
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2007-08-08 | CEO & Director Ms. Catherine M. Szyman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3600 | Website https://www.masimo.com |
Full time employees 3600 | Website https://www.masimo.com | ||
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, methemoglobin, hemoglobin, fractional arterial oxygen saturation, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow respiratory support therapy, neuromodulation technology, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.